We previously identified transforming growth factor (TGF)-b signaling as a fibronectin-independent mechanism of type I collagen fibrillogenesis following adult liver injury. To address the contribution of TGF-b signaling during the development of liver fibrosis, we generated adult mice lacking TGF-b type II receptor (TGF-bIIR) from the liver. TGF-bIIR knockout livers indeed showed a dominant effect in reducing fibrosis, but fibrosis still remained approximately 45% compared with control and fibronectin knockout livers. Unexpectedly, this was accompanied by significant up-regulation of connective tissue growth factor mRNA levels. Organized type I collagen networks in TGF-bIIR knockout livers colocalized well with fibronectin. We provide evidence that elimination of TGF-bIIR is not sufficient to completely prevent liver fibrosis. Our results indicate a TGF-beindependent mechanism of type I collagen production and suggest connective tissue growth factor as its potent mediator. We advocate combined elimination of TGF-b signaling and connective tissue growth factor as a potential therapeutic target by which to attenuate liver fibrosis. (Am J Pathol 2014 http://dx
Liver fibrosis is defined as an abnormal response to persistent liver injury, characterized by the excessive accumulation of collagenous extracellular matrices (ECMs). 1, 2 Liver fibrosis affects tens of millions of people worldwide and is of great clinical significance because normal liver architecture is disrupted and liver function is ultimately impaired. Because there is no effective treatment of liver fibrosis, many patients develop progressive liver cirrhosis, eventually requiring a liver transplant. 3, 4 There is a long-standing concept that cells in culture cannot form a collagen fibril network without the ECM glycoprotein fibronectin. 5 We recently established an adult mouse model lacking liver fibronectin and demonstrated that fibronectin-null livers, in fact, formed collagen fibril networks similarly to wild-type mice in response to carbon tetrachlorideeinduced chronic liver injury. The networks were found to be nucleated by type V collagen, induced by elevated local transforming growth factor (TGF)-b bioavailability. 6 Therefore, we identified two mechanisms of collagen fibrillogenesis in response to liver injury: both fibronectin and TGF-besignaling mediated. Early in the fibrogenic process, inflammatory cytokines are important in initiating repair following injury. TGF-b acts as a fibrogenic master cytokine and plays a pivotal role in the progression of a variety of chronic fibrotic diseases by promoting myofibroblastic differentiation, stimulating synthesis of ECMs, and down-regulating ECM degradation. 7 In TGFbemediated signaling, ligand TGF-bs bind to TGF-b type I and type II receptors that form heterotetrameric complexes. On ligand binding, downstream Smad signaling pathways are initiated. Activated (phosphorylated) Smads translocate to the nucleus where they are involved in the regulation of gene expression. 8, 9 Currently, several monoclonal antibodies and small molecules targeting TGF-b are in the process of clinical application for chronic fibrotic diseases, including liver fibrosis. 10 However, these studies were initiated without knowledge of how TGF-b signaling exerts its action in the development of liver fibrosis.
Elevated TGF-b activity in chronic fibrotic diseases is often accompanied by elevated expression of a matricellular protein, connective tissue growth factor (CTGF/ CCN2). 11 The manifestation of CTGF/CCN2 functions in vivo involves cooperative interactions with costimulatory factors in the microenvironment, such as TGF-b and fibronectin. One hypothesis arising from the in vivo models is that fibrosing liver injuries are exacerbated by the action of TGF-bemediated CTGF/CCN2. 12 Here, we addressed the extent to which fibrosis is dependent on the TGF-b/CTGF/CCN2 axis in chronic liver injury using an adult mouse model lacking liver TGF-b type II receptors (TGF-bIIR).
Materials and Methods

Mice
Because TGF-bIIR exclusively forms heterotetrameric complexes with the type I receptor in response to ligand binding of all TGF-bs, 8, 9 we used TGF-bIIR floxed mice [a gift from Dr. Harold Moses (Vanderbilt University, Nashville, TN)]. 13 Liver TGF-IIR knockout mice were generated by i.p. injections of polyinosinic-polycytidic acid in 4-to 5-week-old TGF-bIIR(fl/fl)/Mx-Cre þ strain.
14 Liver fibronectin knockout mice [fibronectin(fl/fl)/MxCre þ ] were described previously. 6, 15 All mice were maintained and bred at the animal facility in accordance with institutional guidelines. Mice were regularly monitored and had free access to standard mouse chow and water. Mice received humane care in accordance with institutional guidelines.
Induction of Chronic Liver Injury by Carbon Tetrachloride
Chronic liver injury was induced by i.p. administration of the liver-damaging agent carbon tetrachloride solution (Fluka; Sigma-Aldrich, St. Louis, MO) in olive oil [0.5 mL/ kg body weight as 50% (v/v), twice a week for up to 8 weeks] in sex-matched, 12-to 15-week-old mice. 16, 17 Control and mutant mice were derived from the same litters.
Antibodies
The following antibodies were used for the analyses: rabbit polyclonal antibody (pAb; AB765P; Millipore, Billerica, MA) against type I collagen; rabbit monoclonal antibody (E184; Epitomics, Burlingame, CA) against alpha-smooth muscle actin (a-SMA); rabbit pAb (NB100-91994; Novus Biologicals, Littleton, CO) against TGF-bIIR; mouse monoclonal antibody against heat shock cognate protein 70 (HSC70; Santa Cruz Biotechnology, Santa Cruz, CA); chick pAb against fibronectin [a gift from Dr. Staffan Johansson (Uppsala University, Sweden)]; rabbit pAb against phospho-Smad2 [pSmad2; a gift from Dr. Koichi Matsuzaki (Kansai Medical University, Japan)]. Affinitypurified pAb against mouse CTGF/CCN2 was generated by immunization of rabbits to full-length recombinant proteins. Rabbit pAb (ab6992) against CTGF/CCN2 was from Abcam (Cambridge, UK). Fluorescein isothiocyanatee and Cy3-conjugated, and peroxidase-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA). DAPI was from Vector Laboratories (Burlingame, CA). Our and Abcam's CTGF/CCN2 antibodies showed identical tissue and cellular distributions. No nonspecific binding of the anti-rabbit secondary antibody to mouse tissue Ig was confirmed by the immunohistochemical staining with normal rabbit IgG as a primary antibody (data not shown).
Histological Analysis, Immunohistochemistry, and Immunofluorescence
For histological analyses, liver samples were either directly frozen in optimal cutting temperature compound (TissueTek; Sakura Finetek, Torrance, CA) or fixed overnight in 4% paraformaldehyde in phosphate-buffered saline (pH 7.2) and then dehydrated in a graded alcohol series before being embedded in paraffin. Sirius Red staining was performed according to standard protocols. Immunohistochemistry and immunofluorescence studies were performed as described previously. 6, 14 For quantification of the fibrotic areas in response to chronic liver injury, images were captured with the same gain, offset, magnitude, and exposure time. A minimum of five different images were randomly selected and the intensities were quantified using Image-Pro Plus software version 6.1 (Media Cybernetics, Rockville, MD).
Real-Time PCR
Real-time PCR was performed as described previously. 18 The following primers were used: ColIa1 forward, 5
0 . All samples were analyzed in triplicate at a minimum. After the reactions, the specificity of amplifications in each sample was confirmed by dissociation analysis, showing that each sample gave a single melting peak. The relative mRNA levels were normalized to the level of 18S rRNA.
Western Blot Analysis
Western blot analyses were performed as described elsewhere. 19 In some immunoblotting analyses, samples were transferred onto Immobilon-FL polyvinylidene fluoride membranes (Millipore) and probed with primary and IRDye 800CW-or IRDye 680-conjugated secondary antibodies (LI-COR Bioscience, Lincoln, NE). Immunoreactive bands were detected using the Odyssey Infrared Imaging System (LI-COR Bioscience).
TGF-b Bioassay
A mink lung cell line (TMLC) stably transfected with a PAI-1 promoter fused to luciferase was used for the analysis. 20 Active TGF-b levels were measured as described elsewhere. 21 
Data Presentation and Statistical Analysis
All experiments were performed in triplicate at a minimum, on separate occasions, and the data shown were chosen as representative of results consistently observed. Results are presented as means AE SD. Differences between groups were analyzed using the two-sided Student's t-test on raw data. A P value of <0.05 was considered significant.
Results
We previously demonstrated elevated local TGF-b bioavailability in fibronectin knockout livers in response to injury. 6 When chronic liver injury was induced in fibronectin knockout mice with liver-damaging agent carbon tetrachloride at 0.5 mL/kg body weight, the expression of CTGF/CCN2 mRNA levels corresponded to locally activated TGF-b levels at 8 weeks of carbon tetrachloride treatment ( Figure 1 , A and B) (P < 0.05), suggesting an involvement of TGF-b/CTGF/CCN2 in liver fibrosis.
Because both TGF-b and CTGF/CCN2 are identified as regulators of ECM protein transcription, including collagens and fibronectin, 22 we hypothesized that TGF-b/CTGF/ CCN2 pathway activation may be acting as an upstream modulator in the induction of liver fibrosis. To test this hypothesis, we used TGF-bIIR floxed mice and established 
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The American Journal of Pathology -ajp.amjpathol.org (Figure 2A ), indicating that Mx-Cree mediated deletion of the floxed TGF-bIIR gene was complete in all cell types of the liver, both parenchymal and nonparenchymal cells. Because TGF-bIIR is the exclusive type II receptor for all TGF-b ligands and type I receptor complex formation, 8, 9 lack of this receptor abolishes all TGFbemediated signaling in the liver. Chronic liver injury was then induced by carbon tetrachloride. We confirmed by immunohistochemistry that mutant livers did not show any positive staining for TGF-bIIR, whereas control livers showed positive staining in both hepatocytes and nonparenchymal cells ( Figure 2B ). Furthermore, mutant livers showed very weak and diffuse distribution of pSmad2, whereas control livers showed clear nuclear localizations in both some hepatocytes and nonparenchymal cells ( Figure 2C ).
Next, fibrosis was assessed by Sirius Red staining, which directly marks the deposition of ECMs. TGF-bIIR knockout livers showed decreased fibrosis at 8 weeks of treatment, and levels were significantly less than control and fibronectin knockout livers ( Figure 3A) (P < 0.01), indicating that TGF-b signaling is indeed a dominant pathway in the development of fibrosis. However, TGF-bIIR knockout livers did not completely resist fibrosis, which remained at approximately 46.4% and approximately 43.2% of controls and fibronectin knockout livers, respectively ( Figure 3A) . The expression levels of type I collagen mRNA were reduced but remained at approximately 59.1% and approximately 48.3% compared with control and fibronectin knockout livers, respectively ( Figure 3B ). Mutant livers showed a decreased number of a-SMAepositive cells but still remained at approximately 46.8% positive cells compared with controls ( Figure 3C) [26.5 AE 3.7 cells/field in control (field Z 0.036 mm 2 , n Z 8) vs 12.4 AE 4.9 cells/ field in mutant (n Z 8; P < 0.01)]. a-SMA is a marker for myofibroblasts, including hepatic stellate cells, which play a central role in ECM production in response to liver injury. Type I collagen protein levels in mutant livers were also reduced (approximately 56.4% compared with controls), but substantial type I collagen network formations were confirmed by immunohistochemistry (Figure 3, D and E) . Although the expression levels of fibronectin mRNA in mutant livers were down-regulated, organized type I collagen fibril networks colocalized well with fibronectin networks (Figure 3F ), suggesting fibronectin-nucleated type I collagen network formation in TGF-bIIR knockout livers during the development of liver fibrosis.
Surprisingly, we found a 1.94-fold up-regulation of CTGF/CCN2 mRNA level in mutant livers ( Figure 4A ) (P < 0.01). Subsequent immunohistochemical analysis revealed that CTGF/CCN2 proteins in mutant livers localized mainly in the sinusoid ( Figure 4B ). CTGF/CCN2 can 
The American Journal of Pathology -ajp.amjpathol.orgup-regulate ECM production, and increased expression and deposition of CTGF/CCN2 are observed in activated hepatic stellate cells, biliary epithelial cells, and hepatocytes in fibrotic animal liver models. 22 Further immunofluorescence studies revealed that CTGF/CCN2-positive cells predominantly expressed hepatocyte marker albumin ( Figure 4C ). CTGF/CCN2 and myofibroblast marker a-SMA doublepositive cells were detected as a minor proportion (data not shown). Our findings suggest that the participation of CTGF/CCN2 in type I collagen production is TGF-b independent during the development of liver fibrosis.
Discussion
Whether CTGF/CCN2 drives tissue/organ fibrosis has remained a fundamental question for many years. We have recently shown that constitutive overexpression of CTGF/ CCN2 in fibroblasts under the collagen a2(I) fibroblast enhancer results in significant up-regulation of collagen type I mRNA and protein levels in vitro and that CTGF/CCN2 alone is sufficient to cause spontaneous multiorgan fibrotic phenotypes in vivo. 23 Importantly, these CTGF/CCN2-mediated pathways do not involve canonical TGF-b signaling but promote several other signaling pathways. 23 However, the liver did not show significant fibrosis compared to wild type. Here, we demonstrated significant up-regulation of CTGF/CCN2 expression in both TGF-bIIR and fibronectin-null livers in chronic injury. Our results, therefore, indicate a TGF-beindependent mechanism of type I collagen production, and CTGF/CCN2 as a potent mediator in liver fibrosis. Hence, the progression of liver fibrosis requires two hits: the presence or activation of the matricellular protein CTGF/CCN2 and the induction of adult tissue injury. Furthermore, up-regulated expression of CTGF/CCN2 by TGF-beindependent signaling such as IL-13 24 and/or by down-regulation of CTGF/CCN2 scavenger low-density lipoprotein-receptor-related protein 1 25 would be critical in fibronectin/TGF-bIIR double-knockout mice to induce liver fibrosis in chronic injury. This latter speculation for the requirement of adult tissue injury is based on evidence that overexpression of CTGF/CCN2 in concert with signaling pathways associated with chronic fibrosing injuries can lead to the initiation or exacerbation of fibrosis.
12 These findings support the hypothesis that CTGF/ CCN2 plays a role in modifying cellular function during the development of liver fibrosis by sensing changes in the microenvironment through the engagement of molecular binding partners. We propose CTGF/CCN2 as a key element in TGF-beindependent type I collagen production during the development of liver fibrosis. Thus, it remains to be elucidated how the expression of CTGF is regulated in fibronectin/TGF-bIIR double-knockout livers in the development of liver fibrosis.
To our knowledge, this is the first study to extensively examine the effects of TGF-b signaling on the development of liver fibrosis. Currently, several antifibrotic therapies targeting TGF-b are in the process of clinical application for chronic fibrotic diseases, including liver fibrosis.
10 However, our present study provides compelling evidence that elimination of TGF-bIIR is not sufficient to completely prevent liver fibrosis. Clearly, it is vital to generate the most appropriate therapeutic strategy based on a precise molecular framework of targeting pathways. We propose the combined elimination of TGF-b signaling and CTGF/CCN2 could be a potential therapeutic target to attenuate liver fibrosis. This finding is of critical importance to the field of TGF-b research and chronic fibrotic diseases, where the focus is on accelerating the generation of the most effective treatment for patients, and on an optimum drug development, ie, drugs that target the entire, not partial, mechanisms of disease development. ajp.amjpathol.org -The American Journal of Pathology
